论文部分内容阅读
目的 :探讨川芎嗪防治糖尿病视网膜病发生发展的作用机制。方法 :用链尿佐菌素 (streptozocin ,STZ)制作糖尿病大鼠模型 ,分为正常对照组、糖尿病未治疗组、糖尿病川芎嗪治疗组 ,分别于第 4周、12周测体重、血糖、视网膜超氧化物歧化酶 (SOD)活性和丙二醛 (MDA)含量。 12周后处死大鼠取视网膜行透射电镜观察。结果 :第 4周、12周对照组和川芎嗪治疗组血糖均低于未治疗组。SOD含量显著高于未治疗组 ,视网膜超微结构观察 ,结果川芎嗪治疗组与未治疗组对比有明显改善。结论 :川芎嗪能够降低血糖、提高糖尿病大鼠视网膜组织SOD活性 ,增强其抗氧化能力 ,减少MDA的产生 ,改善视网膜组织超微结构病变。提示川芎嗪能防治糖尿病视网膜病的发展
Objective: To investigate the mechanism of ligustrazine in preventing and treating diabetic retinopathy. Methods: Diabetic rats were induced by streptozocin (STZ) and divided into normal control group, untreated diabetic group and ligustrazine-treated diabetic group. Body weight, blood glucose, retinal Superoxide dismutase (SOD) activity and malondialdehyde (MDA) content. After 12 weeks, the rats were sacrificed and the retina was observed by transmission electron microscopy. Results: In the 4th and 12th weeks, the blood glucose of the control group and the ligustrazine group was lower than that of the untreated group. SOD content was significantly higher than the untreated group, the retina ultrastructure observation, the results of ligustrazine treatment group and untreated group significantly improved. CONCLUSION: Ligustrazine can lower blood glucose, increase SOD activity in retina tissue of diabetic rats, enhance its antioxidant capacity, reduce the production of MDA and improve the ultrastructure of retinal tissue. Tip Ligustrazine can prevent the development of diabetic retinopathy